Skip to main content

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
Cancel
×
×
Home
  • Home
Article
  • Cited by 5
  • Cited by
    Crossref Citations
    Crossref logo
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.
    Van der Linden, Martial and Juillerat Van der Linden, Anne-Claude 2016. A life-course and multifactorial approach to Alzheimer’s disease: Implications for research, clinical assessment and intervention practices. Dementia, p. 147130121665727.
    Ehret, Megan J. and Chamberlin, Kevin W. 2015. Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?. Clinical Therapeutics, Vol. 37, Issue. 8, p. 1604.
    Hogan, David B 2014. Long-Term Efficacy and Toxicity of Cholinesterase Inhibitors in the Treatment of Alzheimer Disease. The Canadian Journal of Psychiatry, Vol. 59, Issue. 12, p. 618.
    Ritchie, C.W. and Zhinchin, G. 2013. Low dose, high dose, or no dose: better prescribing of cholinesterase inhibitors for Alzheimer's disease. International Psychogeriatrics, Vol. 25, Issue. 04, p. 511.
    Castro-Puyana, M. Herrero, M. Mendiola, J.A. and Ibáñez, E. 2013. Functional Ingredients from Algae for Foods and Nutraceuticals. p. 534.
    ×
  • Access

Could cholinesterase inhibitors be harmful over the long term?

  • Lon S. Schneider (a1)
Extract

Given the rather modest clinical effects of cholinesterase inhibitors, an important question is: For how long should they be prescribed? The clinical trials that supported marketing of the drugs were only 3–6 months in duration. A couple of 12-month, placebo-controlled donepezil trials showed some advantage for Mini-Mental State Examination (MMSE) scores and maintaining a level of activities of daily living (ADL) function during that interval (Mohs et al., 2001; Winblad et al., 2001). The controversial AD2000 trial in the UK tended to show MMSE and ADL efficacy over at least two years (Courtney et al., 2004), but the authors questioned whether treatment was worthwhile or cost-effective.

    •
      • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Could cholinesterase inhibitors be harmful over the long term?
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Could cholinesterase inhibitors be harmful over the long term?
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Could cholinesterase inhibitors be harmful over the long term?
      Available formats
      ×
Copyright
COPYRIGHT: © International Psychogeriatric Association 2011
References
Hide All
Atri, A., Shaughnessy, L., Locascio, J. J. and Growdon, J. H. (2008). Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Disease & Associated Disorders, 22, 209–221.
Burns, A., Gauthier, S. and Perdomo, C. (2007). Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry, 22, 806–812.
Courtney, C. et al. (2004). Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial [see comment]. Lancet, 363, 2105–2115.
Doody, R. S., Geldmacher, D. S., Gordon, B., Perdomo, C. A., Pratt, R. D. and Donepezil Study Group (2001). Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology, 58, 427–433.
Doody, R. S. et al. (2009). Donepezil treatment of patients with MCI. Neurology, 72, 1555–1561.
Ellis, K. A. et al. (2009). The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. International Psychogeriatrics, 21, 672–687.
Farlow, M. R. et al. (2010). Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. Clinical Therapeutics, 32, 1234–1251.
Feldman, H. H. et al. (2007). Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study [see comment]. Lancet Neurology, 6, 501–512.
Feldman, H. H. et al. (2009). Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. International Journal of Geriatric Psychiatry, 24, 479–488.
Geldmacher, D. S., Provenzano, G., McRae, T., Mastey, V. and Ieni, J. R. (2003). Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. Journal of the American Geriatrics Society, 51, 937–944.
Gill, S. S. et al. (2009). Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Archives of Internal Medicine, 169, 867–873.
Gillette-Guyonnet, S. et al. (2006). Outcome of Alzheimer's disease: potential impact of cholinesterase inhibitors. Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 61, 516–520.
Green, R. C. et al. (2009). Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease. JAMA, 302, 2557–2564.
Hernandez, R. K., Farwell, W., Cantor, M. D. and Lawler, E. V. (2009). Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs New England healthcare system. Journal of the American Geriatrics Society, 57, 1997–2003.
Kavanagh, S., Van Baelen, B. and Schäuble, B. (in press). Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study. Journal of Alzheimer's Disease.
Lopez, O. L. et al. (2009). Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. Journal of Neurology, Neurosurgery & Psychiatry, 80, 600–607.
Mohs, R. C. et al. (2001). A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients [erratum appears in Neurology, 2001, 57, 1942]. Neurology, 57, 481–488.
Petersen, R. C. et al. (2005). Vitamin E and donepezil for the treatment of mild cognitive impairment [see comment]. New England Journal of Medicine, 352, 2379–2388.
Pirttilä, T., Wilcock, G., Truyen, L. and Damaraju, C. V. (2004). Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. European Journal of Neurology, 11, 734–741.
Raschetti, R., Albanese, E., Vanacore, N. and Maggini, M. (2007). Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Medicine, 4, e338.
Raskind, M. A., Peskind, E. R., Truyen, L., Kershaw, P. and Damaraju, C. V. (2004). The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Archives of Neurologyl, 61, 252–256.
Rountree, S., Chan, W., Pavlik, V., Darby, E., Siddiqui, S. and Doody, R. (2009). Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Research & Therapy, 1, 7.
Schneider, L. S. and Qizilbash, N. (2004). Delay in nursing home placement with donepezil [see comment]. Journal of the American Geriatrics Society, 52, 1024–1026.
Schneider, L. S. and Sano, M. (2009). Current Alzheimer's disease clinical trials: methods and placebo outcomes. Alzheimer's and Dementia, 5, 388–397.
Schneider, L. S., Insel, P. S. and Weiner, M. W.(for the Alzheimer's Disease Neuroimaging Initiative) (2011). Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's disease neuroimaging initiative. Archives of Neurology, 68, 58–66.
Small, G. W., Kaufer, D., Mendiondo, M. S., Quarg, P. and Spiegel, R. (2005). Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. International Journal of Clinical Practice, 59, 473–477.
Sona, A. et al. (2012). Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing. International Psychogeriatrics, 24, 196–203.
Winblad, B. et al. (2001). A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD [see comment]. Neurology, 57, 489–495.
Winblad, B. et al. (2008). Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology, 70, 2024–2035.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Psychogeriatrics
  • ISSN: 1041-6102
  • EISSN: 1741-203X
  • URL: /core/journals/international-psychogeriatrics
Please enter your name
Please enter a valid email address
Who would you like to send this to? *

CAPTCHA *

Skip to the audio challenge
×

Metrics

Full text views

Total number of HTML views: 6
Total number of PDF views: 43 *
Loading metrics...

Abstract views

Total abstract views: 145 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 12th June 2018. This data will be updated every 24 hours.

Cancel
Confirm
×